The influence of С.189G>A P.(Val66Met) polymorphism of the BDNF gene on serum leptin levels in Yakuts

Abstract Background The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusion The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

Download Full-text

The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder

Neuroscience Letters ◽

10.1016/j.neulet.2006.07.040 ◽

2006 ◽

Vol 406 (1-2) ◽

pp. 133-137 ◽

Cited By ~ 48

Author(s):

Palmiero Monteleone ◽

Roberta Zanardini ◽

Alfonso Tortorella ◽

Massimo Gennarelli ◽

Eloisa Castaldo ◽

...

Keyword(s):

Eating Disorder ◽

Bulimia Nervosa ◽

Binge Eating ◽

Eating Behavior ◽

Binge Eating Disorder ◽

Bdnf Gene ◽

Val66met Polymorphism

Download Full-text

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)

CNS Spectrums ◽

10.1017/s109285291200051x ◽

2012 ◽

Vol 17 (3) ◽

pp. 155-163 ◽

Cited By ~ 23

Author(s):

Asuka Katsuki ◽

Reiji Yoshimura ◽

Taro Kishi ◽

Hikaru Hori ◽

Wakako Umene-Nakano ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Plasma Levels ◽

Japanese Patients ◽

Bdnf Gene ◽

Major Depressive ◽

Val66met Polymorphism ◽

Catecholamine Metabolites ◽

Bdnf Val66met Polymorphism ◽

Serum Bdnf

ObjectWe investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients.MethodsEighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively.ResultsMirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG).DiscussionThe dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels.ConclusionSerum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD.

Download Full-text